Presentations to Highlight Company's Gene
Therapies for Cancer and Diabetes
AUSTIN,
Texas, May 8, 2023 /PRNewswire/ -- Genprex,
Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a
clinical-stage gene therapy company focused on developing
life-changing therapies for patients with cancer and diabetes,
today announced the Company's participation in the following
upcoming industry and investor conferences to be held in
May 2023.
Event: Sidoti Micro Cap Conference
Conference Dates: May 10 - 11, 2023
Virtual Presentation: Thursday, May
11 at 12:15 p.m. ET in Track
3
Virtual Presentation Link: https://bit.ly/3APq2xY
Presenter: Ryan Confer, Chief
Financial Officer
Mr. Confer will deliver an overview of the Company's pioneering
gene therapies for cancer and diabetes and will be available for
virtual one-on-one meetings with investors through the Sidoti
conference platform.
A recording of this presentation will be available for replay on
Genprex's website for a period of time.
Event: American Society of Gene & Cell Therapy
Annual Meeting
Conference Dates: May 16 - 20, 2023
Genprex's Chief Technology and Manufacturing Officer,
Hemant Kumar, PhD, and Senior Vice
Preisdent of Intellectual Property and Licensing, Thomas Gallagher, will participate in the ASGCT
annual meeting. Both Dr. Kumar and Mr. Gallagher will be available
for in-person meetings with conference attendees.
Event: A.G.P.'s Virtual Healthcare Conference
Conference Date: May 23 – 24, 2023
Several members of the Genprex management team will participate
in the A.G.P. Virtual Healthcare Conference.
For those interested in meeting Genprex management during these
conferences, please request a meeting through the conference
portals or reach out to Investor Relations at
investors@genprex.com.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage
gene therapy company focused on developing life-changing therapies
for patients with cancer and diabetes. Genprex's technologies are
designed to administer disease-fighting genes to provide new
therapies for large patient populations with cancer and diabetes
who currently have limited treatment options. Genprex works with
world-class institutions and collaborators to develop drug
candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches. Genprex's oncology program
utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery
System which encapsulates the gene-expressing plasmids using lipid
nanoparticles. The resultant product is administered intravenously,
where it is taken up by tumor cells that then express tumor
suppressor proteins that were deficient in the tumor.The Company's
lead product candidate, REQORSA® (quaratusugene ozeplasmid), is
being evaluated in three clinical trials as a treatment for
non-small cell lung cancer (NSCLC) and small cell lung cancer
(SCLC). Both NSCLC clinical programs received a Fast Track
Designation from the Food and Drug Administration. Genprex's
diabetes gene therapy approach is comprised of a novel infusion
process that uses an adeno-associated virus (AAV) vector to deliver
Pdx1 and MafA genes directly to the pancreas. In models of Type 1
diabetes, GPX-002 transforms alpha cells in the pancreas into
functional beta-like cells, which can produce insulin but are
distinct enough from beta cells to evade the body's immune system.
In a similar approach, GPX-003 for Type 2 diabetes, where
autoimmunity is not at play, is believed to rejuvenate and
replenish exhausted beta cells.
For more information, please visit the Company's web site at
www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Cautionary Language Concerning Forward-Looking
Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are made on the basis of the current beliefs,
expectations and assumptions of management, are not guarantees of
performance and are subject to significant risks and uncertainty.
These forward-looking statements should, therefore, be considered
in light of various important factors, including those set forth in
Genprex's reports that it files from time to time with the
Securities and Exchange Commission and which you should review,
including those statements under "Item 1A – Risk Factors" in
Genprex's Annual Report on Form 10-K for the year ended
December 31, 2022.
Because forward-looking statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
Genprex's ability to advance the clinical development,
manufacturing and commercialization of its product candidates in
accordance with projected timelines; the timing and success of
Genprex's clinical trials and regulatory approvals; the effect of
Genprex's product candidates, alone and in combination with other
therapies, on cancer and diabetes; Genprex's future growth and
financial status, including Genprex's ability to continue to
obtain capital to meet its long-term liquidity needs on acceptable
terms, or at all; Genprex's commercial and strategic partnerships,
including those with its third party vendors, suppliers and
manufacturers and their ability to successfully perform and scale
up the manufacture of its product candidates; and Genprex's
intellectual property and licenses.
These forward-looking statements should not be relied upon as
predictions of future events and Genprex cannot assure you that the
events or circumstances discussed or reflected in these statements
will be achieved or will occur. If such forward-looking statements
prove to be inaccurate, the inaccuracy may be material. You should
not regard these statements as a representation or warranty by
Genprex or any other person that Genprex will achieve its
objectives and plans in any specified timeframe, or at all. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Genprex disclaims any obligation to publicly update or release any
revisions to these forward-looking statements, whether as a result
of new information, future events or otherwise, after the date of
this press release or to reflect the occurrence of unanticipated
events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn
Dabbs
media@genprex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genprex-to-participate-and-present-at-upcoming-may-industry-and-investor-conferences-301817625.html
SOURCE Genprex, Inc.